Fatigue in Systemic Lupus Erythematosus
Fatigue in Systemic Lupus Erythematosus: Which Variables Play a Role?
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Denizli, Turkey
- Pamukkale University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Being diagnosed with SLE according to the 2019 ACR/EULAR diagnostic criteria
- Being 18 years of age or older
Exclusion Criteria:
- Not being able to speak or understand Turkish fluently
- Having a psychiatric illness that will affect cooperation
- Heart failure or lung pathology that will affect daily life activities
- Additional autoimmune disease
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue Assesment Scale
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
It is a scale consisting 10 items.
The maximum score is 50.
High score indicates high fatigue.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
FACIT Fatigue Scale
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
It is scale consisting 13 items.
Scores range from 0-52.
High score indicates low fatigue
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Exercise Therapy Approach-Biopsychosocial Questionnaire (BETY-BQ)
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
It is a scale consist of 30 items.
Scores range from 0-120.
Higher scores indicate worse biopsychosocial status.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Short Form 36 (SF-36) Health Survey
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
The SF-36 consists of two dimensions, generating a profile of health-related quality of life.These dimensions are: physical health and mental health.
Higher scores indicate better health.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
HEALTH ASSESSMENT QUESTIONNAIRE (HAQ)
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
The scale consists of 20 questions and includes 8 activities.
The total score is obtained by summing the points earned from 8 activities and then dividing that sum by 8. Higher scores indicate worse functional status
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine blood test results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Participants' routine blood test results such as neutrophil (NEU (K/uL)) , monocyte (MONO (K/uL)), eosinophil (EO (K/uL)), leukocyte (WBC (K/uL)), lymphocyte (LYM (K/uL)), platelet (PLT (K/uL)) will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Participants' routine blood test results such as calcium (Ca (mg/dL)), creatinine (mg/dL), c-reactive protein (CRP (mg/L)), uric acid (mg/dL) will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
The participants' rutin blood test such as aspartate aminotransferase (AST IU/L), alanine aminotransferase (ALT IU/L) will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Hematological indices
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR), platelet*neutrophil/lymphocyte (systemic inflammatory index), monocyte/platelet (MTO), neutrophil*monocyte/lymphocyte (systemic inflammatory response index), neutrophil*monocyte*platelet/lymphocyte (systemic inflammation aggregate index) obtained from complete blood counts will be calculated and recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Procolcytonin (PCT (%)), erythrocyte distribution width (RDW (%)), platelet distribution width (PDW (%)) levels will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Erythrocyte distribution width standard deviation (RDW-SD (fL)) will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
C3 complement (g/L) and C4 complement (g/L) levels will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Blood urea nitrogen (BUN (mg/dL)) levels will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
|
Routine Blood Test Results
Time Frame: Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Sedimentation (mm/h) will be recorded.
|
Evaluations started immediately after receiving ethics committee approval and will be completed within 6 months, which is the study period.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Fatigue
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.